Related Experiment Video
Updated: Sep 13, 2025
Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
Published on: August 12, 2014
A randomized controlled trial comparing hydrophilic coated to uncoated polyurethane double J stents: Does it impact
Gaurav Sharma1, Naveen Kumar1, Diptiranjan Bai1
1Department of Urology, Pushpanjali Hospital and Research Centre, Agra, Uttar Pradesh, India.
Introduction:
Advancements in stent materials and designs are aimed at improving stent-related morbidities, lower urinary tract symptoms (LUTSs), pain, and compromised quality of life (QoL). Various stent materials and coatings have been investigated for their impact on stent-related symptoms. This prospective randomized study aimed to compare urinary symptoms and QoL in patients with polyurethane double J (DJ) stents, with or without hydrophilic polyvinylpyrrolidone coating.
Materials And Methods:
Sixty adult patients undergoing endourological procedures and DJ stent placement were randomized into two groups in 2:1 ratio. In 20 patients, polyurethane stents with hydrophilic coating and in 40 patients, stents without hydrophilic coating were placed. In all patients, a stent of 5F diameter and 26 cm length was used. Urinary symptoms, pain, and QoL were assessed at the time of stent removal, i.e., at 3-4 weeks using the validated ureteral stent symptom questionnaire (USSQ).
Results:
The demographic data were comparable in both groups. Patients with hydrophilic stents reported significantly fewer urinary symptoms (mean score 10.75 vs. 15.28, P < 0.001), lower pain scores (1.50 vs. 3.18, P < 0.001), and better QoL scores (3.0 vs. 5.23, P < 0.001). Symptoms such as frequency, nocturia, urgency, and burning micturition were notably reduced in the hydrophilic group. In addition, 60% of patients in the hydrophilic group reported no pain compared to only 7.5% in the nonhydrophilic group (P < 0.001).
Conclusion:
Hydrophilic-coated DJ stents significantly alleviate LUTS and improve QoL, warranting further large-scale research to validate these findings. These findings align with previous studies suggesting that hydrophilic coatings improve stent-related outcomes.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...